definiens

Register Today for The International Symposium for Tissue Phenomics®

Register Today for The International Symposium for Tissue Phenomics®

External image
Definiens invites you to attend The International Symposium for Tissue Phenomics, happening April 26-27, 2016 in Cambridge, Massachusetts. Enjoy expert presentations on immuno-oncology and big data, valuable panel discussions, all while networking with your peers and other industry experts.

Hear speakers from cutting edge organizations such as:

  • Charite
  • INSERM
  • Merck
  • MedImmune
  • I.T.
  • I.H.
  • Providence…

View On WordPress

How to Discover Powerful Tissue-based Prognostic Biomarkers for the Benefit of Individual Patients

How to Discover Powerful Tissue-based Prognostic Biomarkers for the Benefit of Individual Patients

External image

Join us for our November 11 webinar!
Dr. Nathalie Harder will be presenting the Tissue Phenomics® methodology to discover new tissue-based diagnostics using image and clinical data and known clinical outcome for the benefit of individual patients.

You can select from one of two different broadcast times to watch this webinar.

Date: Wednesday, November 11, 2015
Broadcast #1:2pm GMT (UK) / 3pm CET…

View On WordPress

Applying Tissue Phenomics® to Clinical Questions for Patient Stratification

Applying Tissue Phenomics® to Clinical Questions for Patient Stratification

External image
Join us for our September 23 webinar on Applying Tissue Phenomics® to Clinical Questions for Patient Stratification. Dr. Peter Caie will be presenting how Tissue Phenomics can be utilized to identify previously undiscovered prognostic and predictive image-based features or combinations of features for patient stratification.

For your convenience, select from one of two different broadcast times…

View On WordPress

Definiens Strengthens Tissue Phenomics Research with microDimensions’ Technology

microDimensions, global provider of state-of-the-art digital pathology software and services, won Definiens as one of their customers. Definiens is the pioneer in Tissue Phenomics® solutions for diagnostics development and commercialization and was recently acquired by MedImmune, the biologics research and development arm of AstraZeneca.

As a new customer of microDimensions, Definiens will be…

View On WordPress

Webinar from Definiens: Clinical Trial Patient Stratification with Quantitative IHC Assays

Webinar from Definiens: Clinical Trial Patient Stratification with Quantitative IHC Assays

External image

External image

Sharon Moulis, PhD

Join us for our May 13 webinar on How to Develop Fit-for-Purpose Quantitative IHC Assays to Enable Clinical Trial Patient Stratification. Dr. Sharon Moulis will be presenting how traditional methods of IHC assay design can be modified with the use of quantitative image analysis to develop robust and powerful quantitative IHC assays. These robust assays can then withstand…

View On WordPress

Definiens to Host International Symposium for Tissue Phenomics®

MUNICH–(BUSINESS WIRE)–

Definiens, the pioneer in Tissue Phenomics solutions for diagnostics development, has announced that registration is now open for the company’s upcoming conference, The International Symposium for Tissue Phenomics, from April 26-27, 2016 in Cambridge, Massachusetts.

Tissue Phenomics, the use of unique tissue signatures correlated to genetic or patient outcome data to develop precise and powerful tissue-based diagnostics, continues to be a key driver in the growth of personalized medicine in oncology. This year’s Symposium will focus on new advancements and important work being done in the space, specifically “The Future of Cancer Dx,” as well tissue-based immunoprofiling, big data and data integration, and digital pathology and diagnostics in immuno-oncology.

The symposium will feature presentations and discussions by leading distinguished researchers and speakers, including:

  • Joseph Beecham, Nanostring Technologies, Inc.
  • Carlo Bifulco, Providence Health & Services, Inc.
  • Gerd Binnig, Definiens AG
  • Peter Caie, University of St. Andrews
  • Manfred Dietel (Chair), Charité
  • Belma Dogdas, Merck & Co., Inc.
  • Bernhard Fox (Chair), Providence Health & Services, Inc.
  • Jerôme Galon, Inserm
  • James Gulley, NIH
  • Michael Hehenberger, IBM
  • Ron Herbst, MedImmune
  • Jeff Hodgin, University of Michigan Medical School
  • Dirk Jäger, NCT Heidelberg
  • Trevor McKee, Princess Margaret Cancer Centre
  • Holger Moch, University of Zurich
  • Bob Silverman, Gilde Healthcare

“The annual Symposium has become a central meeting for discussion on cancer companion diagnostics and personalized medicine,” said Thomas Heydler, CEO, Definiens. “Significant advancements are being made with Tissue Phenomics, and this event, which brings together some of the greatest minds in the industry, is critical to continuing the dialogue, collaboration and education needed for the progress of tissue-based diagnostics and immune-oncology.”

The symposium will take place from April 26-27, 2016 at the Hotel Marlowe in Cambridge, Massachusetts. Register online at http://www.cvent.com/d/sfqk2w.

For more information, please contact Lina Willis, global marketing and conference manager at lwillis@definiens.com.

About Definiens

Definiens is the pioneering provider of Tissue Phenomics® solutions for biomarker and companion diagnostics development. Definiens’ technology empowers smarter tissue-based diagnostics by leveraging quantitative tissue readouts and other big data sources. By enabling the development of powerful and precise assays for patient stratification and clinical trial enrollment, Definiens aims to dramatically improve patient outcomes. Definiens’ Tissue Phenomics approach was awarded the 2013 Frost and Sullivan Company of the Year Award for Global Tissue Diagnostics and Pathology Imaging. For more information, please visit: www.definiens.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160201005148/en/

.bwalignc {text-align: center !important;} .bwlistitemmargb {margin-bottom: 10.0px !important;} ;}